The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.78 and fluctuated between $0.7989 as its day high and $0.7200 as its day low. The current market capitalization of SELLAS Life Sciences Group Inc is $32.80M. A total of 1.41 million shares were traded on the day, compared to an average of 998.75K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, SLS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for SLS in the last 3 months, the mean price target is $6.83 with high estimates of $9.00 and low estimates of $4.00. In terms of 52-week highs and lows, SLS has a high of $3.98 and a low of $0.50.
As of this writing, SLS has an earnings estimate of $SELLAS Life Sciences Group, Inc per share for the current quarter. EPS was calculated based on a consensus of Schlumberger N.V. estimates, with a high estimate of $Celestica, Inc. per share and a lower estimate of $iShares Silver Trust.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. SLS’s latest balance sheet shows that the firm has $21.36M in Cash & Short Term Investments as of fiscal 2021. There were $808.00k in debt and $4.98M in liabilities at the time. Its Book Value Per Share was -$0.13, while its Total Shareholder’s Equity was $20.35M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SLS is Buy with a score of 5.00.